Biogen has decided to close down its digital health unit, formed just two years ago, as part of a major cost-reduction drive that has already claimed thousands of jobs.
AstraZeneca’s Tagrisso could face some serious competition as a first-line targeted therapy for advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC), in
The US government has set aside a $104 million pot of funding for research into bacterial behaviour and antibiotic resistance, in the hope of speeding up diagnosis and ena
BridgeBio Pharma has raised $250 million from the sale of nine million shares that is earmarked for the commercial launch of its acoramidis drug for transthyretin amyloido
Novartis’ former chief medical officer John Tsai has returned to a senior position in biopharma, taking the role of chief executive of UK start-up Forcefield Therapeutics.
Ionis Pharma is preparing to file for regulatory approval of its experimental therapy olezarsen for familial chylomicronaemia syndrome (FCS) in the US and Europe after the
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.